Why GLP matters in drug development
Non-clinical data generated under Good Laboratory Practice (GLP) conditions forms the basis for critical regulatory decisions, including progression to first-in-human trials. Regulatory authorities rely on GLP-compliant studies to evaluate the safety profile of new chemical entities, biologics and formulations before clinical exposure.
GLP compliance helps ensure that non-clinical findings are supported by reliable and traceable evidence, giving confidence to regulators, sponsors and stakeholders throughout the development journey.
GLP compliance helps ensure that:
- Study conduct follows approved protocols and documented procedures.
- Results are scientifically sound, reliable and defensible.
- Data is traceable, auditable and reproducible.
A structured GLP framework also supports consistent documentation and accountability across study activities. These practices help sponsors assess study findings and prepare the supporting evidence required for development decisions.
Explore our non-clinical development services to learn more about the support available for your research programme.
Core principles of GLP compliance
GLP is built on structured processes that govern every stage of non-clinical research. These principles collectively safeguard data quality and reliability.
Key elements of GLP
- Clearly defined study plans and approved protocols
- Qualified personnel and documented training
- Controlled test systems and validated methods
- Accurate data recording and secure archiving
- Independent quality assurance oversight
Clear responsibilities, appropriate facilities, controlled procedures and reliable records help establish a consistent framework for conducting and reviewing non-clinical studies.
Learn more about our scientific services and how they can support your drug development programme.
Quality assurance and oversight
An independent Quality Assurance (QA) function is central to GLP compliance. QA units monitor study conduct, verify adherence to protocols and audit final reports to confirm accuracy and completeness before regulatory submission.
This oversight helps ensure that deviations are identified, addressed and documented in alignment with applicable regulatory expectations.
Strong quality systems also support accountability throughout a study, from planning and sample handling to data review, reporting and archiving. Documented processes make it easier to trace decisions and demonstrate how study results were generated.
Key takeaway
GLP compliance strengthens confidence in non-clinical research outcomes, supports regulatory decision-making and helps advance safe and effective therapies for patients.
Advance your drug development with Adgyl Lifesciences
From non-clinical studies to regulatory support, our scientific experts are ready to discuss how we can support your next project.